Celgene Corporation (NASDAQ: CELG) is down about 35 percent year-over-year, and as management resists challenges to critical Revlimid patents, analysts are at odds about where the stock could head from here.
Bernstein analyst Aaron Gal upgraded Celgene from Market-Perform to Outperform and cut the price target from $121 to $102.
Argus analyst David Toung downgraded the stock from Buy to Hold.
The Bull Thesis
By Bernstein’s assessment, Celgene’s current discounted cash flow reflects the worst possible outcome for the Revlimid trial — a result that could push the launch to April 2020. Gal expects a victory in the second half of 2019 or a settlement even earlier.
His bullishness is bolstered by Celgene’s potential to secure four significant, valuation-driving approvals in the next two years or, in the case that valuation remains depressed, to pursue governance or ownership changes.
“This is fundamentally a valuation call on a 'cliff' company,” Gal said in a Wednesday note.
The Bear Thesis
Toung is less optimistic about Revlimid’s legal issues, which could increase share volatility with an adverse ruling.
“We remain concerned about the company’s overreliance on Revlimid (65 percent of revenue) and about setbacks in its product pipeline,” Toung said. “While Celgene has settled one legal challenge to its Revlimid patents, it continues to fight challenges from other potential generic competitors.”
His downgrade also accounts for a perceived drop in financial strength after Celgene took on more debt to fund acquisitions.
Celgene shares were up 0.64 percent at $77.10 after the open Wednesday.
Celgene Forges Oncology Partnership With Germany's Evotec
Analyst: Trump's 'Naming And Shaming' Campaign To Build Pharma Headline Risk
Latest Ratings for CELG
|May 2018||Bernstein||Upgrades||Market Perform||Outperform|
|May 2018||Morgan Stanley||Maintains||Equal-Weight||Equal-Weight|
View More Analyst Ratings for CELG
View the Latest Analyst Ratings
See more from Benzinga
- Analyst: Trump's 'Naming And Shaming' Campaign To Build Pharma Headline Risk
- Baird: Biogen A Buy On M&A Prospects, Underappreciated Franchises
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.